1. Successful treatment of three patients with organizing pneumonia associated with rheumatoid arthritis using clarithromycin and prednisolone
   Masashi Ohe et al, 2017, DD&T CrossRef
2. Immune-Related Adverse Events: Pneumonitis
   Akash Jain et al, 2018 CrossRef
3. Long-term macrolides in diffuse interstitial lung diseases
   Paola Faverio et al, 2017, Eur Respir Rev CrossRef
4. Pneumonitis after precision oncology therapies: A concise review
   Akash Jain et al, 2018, J Immunother Precis Oncol CrossRef
5. Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment
   E. Radzikowska et al, 2016 CrossRef
6. Acute fibrinous organising pneumonia presenting as a cavitary lung lesion and treatment response to azithromycin
   Waqas Aslam et al, 2019, BMJ Case Rep CrossRef
7. Idiopathic interstitial pneumonias
   Alexander Averyanov et al, 2020 CrossRef
8. The Effectiveness of Low-dose Azithromycin in Relapsing Cryptogenic Organizing Pneumonia
   Tommaso D’Elia, 2016, Clinical Pulmonary Medicine CrossRef
9. Increasing Role of Macrolide Anti-inflammatory Therapy in Secondary Organizing Pneumonia
   Arjan S. Flora et al, 2017, American Journal of Therapeutics CrossRef
10. Antibiotics in interstitial lung diseases
    Davide Biondini et al, 2017 CrossRef
11. Long-term oral antibiotic treatment: why, what, when and to whom?
    Eva Van Braeckel et al, 2017 CrossRef
12. Immune-Related Adverse Events: Pneumonitis
    Linda Zhong et al, 2020 CrossRef
13. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease
    David Smith et al, 2020, Thorax CrossRef
14. Cardiovascular side-effects of common antibiotics
    Francesco Amati et al, 2020 CrossRef
15. Cryptogenic organizing pneumonia masquerading as lung carcinoma: A case report and review of the literature
    Ji‑Ping Huo et al, 2017, Exp Ther Med CrossRef
16. SARS-CoV-2 organising pneumonia: ‘Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’
    Pierre Kory et al, 2020, BMJ Open Resp Res CrossRef
17. Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 4. Cryptogenic Organizing Pneumonia
    Sue In Choi et al, 2021, Tuberc Respir Dis CrossRef
18. Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease
    Ganesh Raghu et al, 2021, Eur Respir Rev CrossRef
19. Pulmonary Toxicities of Immunotherapy
    Mehmet Altan et al, 2021 CrossRef
20. What you need to know about: organising pneumonia
    Lavanya Anandan et al, 2022, Br J Hosp Med CrossRef
21. Extracorporeal Membrane Oxygenation Supported Transbronchial Cryobiopsy in the Diagnosis of Severe Organizing Pneumonia: A Case Report
    Xiaoyan Zhang et al, 2022, Front. Med. CrossRef
22. Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics
    Christopher Lau et al, 2022, Pulmonary Pharmacology & Therapeutics CrossRef
23. Update on cryptogenic organizing pneumonia
    Elzbieta Radzikowska et al, 2023, Front. Med. CrossRef
24. Secondary organizing pneumonia after coronavirus disease (literature review)
    L. S. Gofman et al, 2023, SJCEM CrossRef
25. Safety and efficacy of bronchoscopy with transbronchial lung biopsy in interstitial lung diseases: our experience
    Neenu N et al, 2023 CrossRef
26. How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients
    Yu Kuang Lai et al, 2024 CrossRef
27. Cryptogenic organizing pneumonia caused by solanine: A case report
    Linying Wang et al, 2024 CrossRef